Franco Noventa

Franco Noventa

Auto-generated profile, based on publicly available information

Franco Noventa

QUOVADIS Associazione no-profit, Padova, Italy

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 January 2020 in Liver International
Verified
Journal Article
Closed access
PDF file
ASAlessandro Soria
Alessandro Soria
MFMarco Fava
Marco Fava
DBDavide Paolo Bernasconi
Davide Paolo Bernasconi
GLGiuseppe Lapadula
Giuseppe Lapadula
ECElisa Colella
Elisa Colella
SFSTEFANO FAGIUOLI
STEFANO FAGIUOLI

28 March 2023 in EP Europace
Verified
Journal Article
Open access
PDF file
GPGianni Pastore
Gianni Pastore
Matteo BertiniMatteo Bertini
Matteo Bertini
CBCarlo Bonanno
Carlo Bonanno
GCGiovanni Coluccia
Giovanni Coluccia
GDGabriele Dell'ERa
Gabriele Dell'ERa
FNFranco Noventa
Franco Noventa
Aims: In patients with prolonged atrioventricular (AV) conduction and pacemaker (PM) indication due to sinus node disease (SND) or intermittent AV-block who do not need continuous ventricular pacing (VP), it may be difficult to determine which strategy to adopt. Currently, the standard of care is to minimize unnecessary VP by specific VP avoidance (VPA) algorithms. The superiority of this strategy over standard DDD or DDD rate-responsive (DDD/DDDR) in improving clinical outcomes is controversial, probably owing to the prolongation of the atrialventricular conduction (PR interval) caused by the algorithms. Conduction system pacing (CSP) may offer the most physiological-VP approach, providing appropriate AV conduction and preventing pacing-induced dyssynchrony. Methods and results: PhysioVP-AF is a prospective, controlled, randomized, single-blind trial designed to determine whether atrial-synchronized conduction system pacing (DDD-CSP) is superior to standard DDD-VPA pacing in terms of 3-year reduction of persistent-AF occurrence. Cardiovascular hospitalization, quality-of-life, and safety will be evaluated. Patients with indication for permanent DDD pacing for SND or intermittent AV-block and prolonged AV conduction (PR interval > 180 ms) will be randomized (1:1 ratio) to DDD-VPA (VPA-algorithms ON, septal/apex position) or to DDD-CSP (His bundle or left bundle branch area pacing, AV-delay setting to control PR interval, VPA-algorithms OFF). Approximately 400 patients will be randomized in 24 months in 13 Italian centres. Conclusion: The PhysioVP-AF study will provide an essential contribution to patient management with prolonged AV conduction and PM indication for sinus nodal disease or paroxysmal 2nd-degree AV-block by determining whether CSP combined with a controlled PR interval is superior to standard management that minimizes unnecessary VP in terms of reducing clinical outcomes.

5 May 2026 in EP Europace
Verified
Journal Article
Open access
GPGianni Pastore
Gianni Pastore
LMlina marcantoni
lina marcantoni
MSMatteo Spoladori
Matteo Spoladori
FDFrancesco Deluca
Francesco Deluca
SVSimone Valenza
Simone Valenza
FNFranco Noventa
Franco Noventa

10 June 2016 in EP Europace
Verified
Journal Article
Open access
PDF file
FZFrancesco Zanon
Francesco Zanon
LMlina marcantoni
lina marcantoni
GPGianni Pastore
Gianni Pastore
EBEnrico Baracca
Enrico Baracca
RFRoberto Floris
Roberto Floris
FPFrits Prinzen
Frits Prinzen
Introduction: The clinical response to cardiac resynchronization therapy (CRT) is variable. The optimization of the left ventricle (LV) pacing site increases the number of responder to CRT. The Multipoint (MPP) pacing could further increase hemodynamic response to and clinical outcome of CRT. The purpose of our study was to test the hypothesis that pts optimized at implant and treated with MPP experience superior long-term clinical outcomes than conventional CRT pts. Methods: 110 HF pts treated for 1 year with either conventional CRT(STD, N = 54), CRT with hemodynamic and electrical optimized LV pacing site (OPT, N = 36), and with optimized LV pacing site + MPP (OPT-MPP, N = 20) were evaluated to determine CRT response relative to baseline. Responders were classified in terms of 1-year reduction in end-systolic volume index≥ 15%, reduction in NYHA class ≥ 1, and PACKER score variation (NYHA response with no HF-related hospitalization or death). Results: In terms of ESVi, 55.6% of STD, 72.2% of OPT, and 90.0% of OPT-MPP pts were responders. In terms of NYHA, 66.7% of STD, 77.8% of OPT, and 95.0% of OPT-MPP pts responded, with more MPP pts experiencing a NYHA downgrade of 2 classes or beyond. Likewise, 59.3.0% of STD, 66.7% of OPT, and 90.0% of OPT-MPP pts exhibited a 1-year PACKER response. Conclusions: Optimization of LV pacing sites by means of Hemodynamic and electrical delay plus MPP showed an enhanced potential to reverse the progression of HF and improve clinical outcomes, relative to conventional CRT.


1 February 2019 in Digestive and Liver Disease
Verified
Journal Article
Closed access
MGM. Gambato
M. Gambato
ASA. Spinetti
A. Spinetti
LPL. Pasulo
L. Pasulo
RDR. D’ambrosio
R. D’ambrosio
Massimo PuotiMassimo Puoti
Massimo Puoti
SFSTEFANO FAGIUOLI
STEFANO FAGIUOLI